Annexon (NASDAQ:ANNX) Posts Quarterly Earnings Results, Meets Estimates

Annexon (NASDAQ:ANNX) released its earnings results on Monday. The company reported ($0.23) EPS for the quarter, meeting analysts’ consensus estimates of ($0.23), Yahoo Finance reports.

Annexon Stock Performance

NASDAQ:ANNX opened at $5.69 on Wednesday. The firm has a 50-day simple moving average of $5.53 and a two-hundred day simple moving average of $5.37. The firm has a market cap of $525.37 million, a P/E ratio of -3.87 and a beta of 1.29. Annexon has a fifty-two week low of $1.57 and a fifty-two week high of $8.40.

Wall Street Analyst Weigh In

ANNX has been the subject of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Wednesday, June 5th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Annexon in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Tuesday. Finally, Wells Fargo & Company decreased their target price on shares of Annexon from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, May 15th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $15.33.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.